- Home
- AKAN vs PRFX Comparison
AKAN vs PRFX Comparison
Compare AKAN & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKAN
- PRFX
- Stock Information
- Founded
- AKAN 2021
- PRFX 2007
- Country
- AKAN Canada
- PRFX Israel
- Employees
- AKAN N/A
- PRFX N/A
- Industry
- AKAN Medicinal Chemicals and Botanical Products
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- AKAN Health Care
- PRFX Health Care
- Exchange
- AKAN Nasdaq
- PRFX Nasdaq
- Market Cap
- AKAN 2.9M
- PRFX 2.8M
- IPO Year
- AKAN 2022
- PRFX 2020
- Fundamental
- Price
- AKAN $3.33
- PRFX $1.34
- Analyst Decision
- AKAN
- PRFX Hold
- Analyst Count
- AKAN 0
- PRFX 1
- Target Price
- AKAN N/A
- PRFX N/A
- AVG Volume (30 Days)
- AKAN 158.8K
- PRFX 8.8M
- Earning Date
- AKAN 10-29-2025
- PRFX 09-26-2025
- Dividend Yield
- AKAN N/A
- PRFX N/A
- EPS Growth
- AKAN N/A
- PRFX N/A
- EPS
- AKAN N/A
- PRFX N/A
- Revenue
- AKAN $836,664.00
- PRFX N/A
- Revenue This Year
- AKAN N/A
- PRFX N/A
- Revenue Next Year
- AKAN N/A
- PRFX N/A
- P/E Ratio
- AKAN N/A
- PRFX N/A
- Revenue Growth
- AKAN 97.47
- PRFX N/A
- 52 Week Low
- AKAN $2.91
- PRFX $1.25
- 52 Week High
- AKAN $8.75
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- AKAN 41.55
- PRFX 44.57
- Support Level
- AKAN $3.14
- PRFX $1.32
- Resistance Level
- AKAN $3.68
- PRFX $1.47
- Average True Range (ATR)
- AKAN 0.37
- PRFX 0.12
- MACD
- AKAN -0.03
- PRFX -0.02
- Stochastic Oscillator
- AKAN 15.20
- PRFX 4.17
About AKAN Akanda Corp.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.